Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02535286 |
| Title | Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | TG Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | New York | New York | 10065 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Durham | North Carolina | 27710 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Philadelphia | Pennsylvania | 19104 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Seattle | Washington | 98109 | United States | Details |